Recent data from tumour experimental models have shown that blocking TIMD4 can enhance the anti‐tumour efficacy of immune checkpoint inhibitors (ICI, anti‐PD1) and adoptive T‐cell (ACT) therapies in mouse models [28]. This evidence concerns the gene TIMD4 and neoplasm.